These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1021 related items for PubMed ID: 9432985

  • 41. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy.
    Khong HT, Rosenberg SA.
    J Immunol; 2002 Jan 15; 168(2):951-6. PubMed ID: 11777994
    [Abstract] [Full Text] [Related]

  • 42. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
    Komatsu N, Jackson HM, Chan KF, Oveissi S, Cebon J, Itoh K, Chen W.
    Mol Immunol; 2013 Jul 15; 54(3-4):465-71. PubMed ID: 23454162
    [Abstract] [Full Text] [Related]

  • 43. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N.
    J Immunol; 2003 Dec 01; 171(11):6283-9. PubMed ID: 14634146
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K, Spruill G, Rhoderick J, Spielman J, Savaraj N, Podack ER.
    Cancer Res; 1999 Sep 15; 59(18):4642-50. PubMed ID: 10493519
    [Abstract] [Full Text] [Related]

  • 48. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C.
    Cancer Res; 2003 Oct 15; 63(20):6948-55. PubMed ID: 14583496
    [Abstract] [Full Text] [Related]

  • 49. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs.
    Gnjatic S, Atanackovic D, Matsuo M, Jäger E, Lee SY, Valmori D, Chen YT, Ritter G, Knuth A, Old LJ.
    J Immunol; 2003 Feb 01; 170(3):1191-6. PubMed ID: 12538675
    [Abstract] [Full Text] [Related]

  • 50. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
    Maruta M, Ochi T, Tanimoto K, Asai H, Saitou T, Fujiwara H, Imamura T, Takenaka K, Yasukawa M.
    Sci Rep; 2019 Sep 16; 9(1):13293. PubMed ID: 31527633
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X, Xu Y, Xiong W, Yin B, Huang Y, Chu J, Xing C, Qian C, Du Y, Duan T, Wang HY, Zhang N, Yu JS, An Z, Wang R.
    J Immunother Cancer; 2022 Mar 16; 10(3):. PubMed ID: 35338087
    [Abstract] [Full Text] [Related]

  • 57. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
    Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA.
    J Immunol; 2005 Apr 01; 174(7):4415-23. PubMed ID: 15778407
    [Abstract] [Full Text] [Related]

  • 58. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T, Irie RF, Morton DL, Hoon DS.
    Cell Immunol; 1997 Jun 15; 178(2):162-71. PubMed ID: 9225007
    [Abstract] [Full Text] [Related]

  • 59. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
    Bao L, Dunham K, Lucas K.
    Cancer Immunol Immunother; 2011 Sep 15; 60(9):1299-307. PubMed ID: 21626030
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.